Navigation Links
Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
Date:3/31/2011

ROCKVILLE, Md., March 31, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD).  The trial is expected to begin during the second half of 2011.  Tasimelteon is currently being evaluated in Phase III clinical trials for the treatment of Non-24-Hour Sleep/Wake Disorder (N24HSWD) in blind individuals without light perception.

"Research suggests that misalignment of the circadian rhythm, or body clock, may have significant health consequences, including those related to mood disorders such as major depression," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.  "Treating depression with a circadian regulator is a novel concept, which has more recently become an area of focus for the pharmaceutical industry. Expansion of our investigations into MDD is consistent with our vision for Vanda as a leading specialty pharmaceutical company focused on the development and commercialization  of differentiated products for central nervous system disorders."

There is considerable evidence that suggests circadian rhythm disturbances are important in the pathophysiology of mood disorders. Depressed patients often show altered circadian rhythms, sleep disturbances, and diurnal mood variation. Chronotherapies, including bright light exposure, have been successfully used to treat seasonal and non-seasonal mood disorders. These observations suggest that aberrations of the circadian clock may significantly contribute to the production of the symptoms of MDD and therefore treatments that aim at restoring the regulation of the circadian clock could prove beneficial (1).

Despite the availability of a number of treatments for MDD, there remains a significant unmet medical need.  In the large Star*D study spon
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Washington , 6. März 2015 /PRNewswire/ ... von Röntgenstrahlen, feierte auf dem European Congress ... , Österreich, die 1.000. Installation seines ... Logo - http://photos.prnewswire.com/prnh/20150304/179432LOGO ... Dosimeter, der in Echtzeit Informationen über die ...
(Date:3/6/2015)... 2015  The German Court of Appeal has ruled that ... regimen patent for Alimta® (pemetrexed disodium) would not be infringed ... salt form of pemetrexed in Germany ... The German Court ruled in favor of the generic ... Actavis. This decision vacated the prior decision of the Regional ...
(Date:3/6/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rvhg65/european_patient ) ... Handling Equipment Market by Product, by Type of Care, ... report to their offering. The ... at a double-digit CAGR of 11.4% to reach $5,150.2 ... rising geriatric population, increasing incidences of lifestyle diseases, and ...
Breaking Medicine Technology:Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 2Unfors RaySafe, ein Unternehmen von Fluke Biomedical, feiert 1.000. Installation seines Systems zur Echtzeit-Strahlendosimetrie 3German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 3European Patient Handling Equipment (Wheelchair, Scooters, Bathroom Safety Supply, Mechanical, Ambulatory) Market 2015-2019 2European Patient Handling Equipment (Wheelchair, Scooters, Bathroom Safety Supply, Mechanical, Ambulatory) Market 2015-2019 3
... 2011 Stryker Corporation (NYSE: SYK ) announced ... quarter of 2010, representing an 8.8% increase over net sales ... were $7,320 million for the year ended December 31, 2010, ... for the year ended December 31, 2009. On a constant ...
... MORRISTOWN, N.J., Jan. 10, 2011 Watson Pharmaceuticals, Inc. (NYSE: ... hosting an Investor Day on January 21, 2011 in New ... a.m., Eastern Time and will be simultaneously webcast. ... preliminary outlook for 2011. The presenters will include: Paul Bisaro, ...
Cached Medicine Technology:Stryker Increases Expected 2010 Results and Provides 2011 Outlook 2Stryker Increases Expected 2010 Results and Provides 2011 Outlook 3Stryker Increases Expected 2010 Results and Provides 2011 Outlook 4Stryker Increases Expected 2010 Results and Provides 2011 Outlook 5Stryker Increases Expected 2010 Results and Provides 2011 Outlook 6Stryker Increases Expected 2010 Results and Provides 2011 Outlook 7
(Date:3/6/2015)... Ticket Down is a reliable source for authentic ... California. This state-of-the-art stadium opened on July 17, 2014 ... , The “Kick the Dust Up Tour” featuring country megastar ... west coast and Levi’s Stadium. The show at the new ... 29 and fans of the award-winning artist will be able ...
(Date:3/6/2015)... Jose, California (PRWEB) March 06, 2015 ... also known as the pharmacokinetics of a drug refers ... a pharmaceutical compound inside an organism. When toxicity studies ... ADME-Tox or ADMET or ADME/Tox. Increasing focus on lowering ... adoption of ADME-toxicology testing worldwide. The traditional drug development ...
(Date:3/6/2015)... Parents need to start the discourse with their ... School programs like DARE, or Drug Abuse Resistance Education ... Overdose Prevention and Education has already impacted a collective ... on Feb. 27th. As teens continue to suffer fatal ... proponents are lobbying Florida to pass The Overdose Prevention ...
(Date:3/6/2015)... 06, 2015 Johnson & Johnson and ... on March 5, 2015 in Superior Court in the ... documents, a jury of 12 awarded Mrs. Perry $700,000 ... implanted with an Ethicon TVT Abbrevo plastic sling for ... three women also awarded $5 million in punitive damages. ...
(Date:3/6/2015)... Washington, DC (PRWEB) March 06, 2015 ... the nation’s only comprehensive source for key trends and ... specialty spend, medical injectables. Executives from Magellan Rx Management ... Pharmacy Trend Report: Discover Your Hidden Specialty Drug Spend,” ... Atlantic Information Services, Inc. , Specialty drug spend makes ...
Breaking Medicine News(10 mins):Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 2Health News:Cheap Luke Bryan Tickets at Levi's® Stadium in Santa Clara, CA: Ticket Down Slashes Ticket Prices on Luke Bryan Concert Tickets in Santa Clara at the New Levi's® Stadium 3Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Growing Need to Reduce Drug Development Costs Drives the Global ADME-Toxicology Testing Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:A Harbor Village Detox Clinical Psychologist Encourages School Programs like NOPE to Positively Impact Awareness of Substance Use Disorders 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... AtlantaNAP ( www.atlantanap.com ), a ... Information Designs.As a strategic initiative to consolidate their internal ... for a true Tier III facility, Health Information Designs ... facility for its core operations. The facility will ...
... Los Angeles, London, New Delhi, Singapore and Washinton DC (18 ... Autism , published by SAGE, estimate the annual costs ... billion a year. The costs of supporting children with ASDs ... each year for adults. The findings will be presented at ...
... Plans and Cut CostsAMHERST, N.Y., May 18 StreetWise HSA(SM) ... education. StreetWise HSA (SM), which is now available nationally, ... Account plans and cut costs. StreetWise HSA(SM) is the ... , Delivers an online ...
... Carnival Corporation & plc (NYSE/LSE: CCL; NYSE CUK) ... per share, the majority of which will be incurred ... result of modifications to cruise itineraries for the six-week ... Centers for Disease Control (CDC) recommendation against non-essential travel ...
... Locate Hard-to-Find-VeinsAdvances Quality of Patient Care in Venipuncture, ... May 18 AccuVein ... the world,s first hand-held, non-contact vein illumination device ... starts and blood draws (venipuncture) can be a ...
... Supply Chain Top 25 to Be Announced at EventBOSTON, May ... research firm focused on the global supply chain and its ... Supply Chain Executive Conference, to be held at The Phoenician ... includes a keynote address from Michael Eisner, CEO of Walt ...
Cached Medicine News:Health News:GNAX/AtlantaNAP Announces Newest Client, Health Information Designs 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:StreetWise HSA(SM) Launched Nationally: First Low-Cost, Customizable Platform for Employee HSA Education 2Health News:Carnival Corporation & plc Reports Financial Impact of Itinerary Changes Responding to H1N1 Influenza Mexico Travel Advisory; Plans Rapid Return to Popular Mexican Ports 2Health News:Video: AccuVein Launches First Portable, Non-Contact Vein Illumination Device 2Health News:Video: AccuVein Launches First Portable, Non-Contact Vein Illumination Device 3Health News:AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference 2
... is a highly retentive, dispersive viscoelastic. ... weight, low pseudoplasticity and low surface ... and excellent tissue protection. It is ... (catalog number 8065183905) or as part ...
... VISUCAM DigitalCameras permit fundus imaging and ... operation without any need for eyepieces ... findings. Image recording and display is ... utilizes the ophthalmoscope principle of modern ...
... planning workstation is used to plan precisely ... Planning Workstation, the surgeon can simulate the ... the patient. This enables the selection of ... material waste and procedural costs. The surgeon ...
... The ARIS A utomated R ... revolutionary, patented technology which provides rapid and automated ... allows eye care professionals to screen and ... in less time and at ...
Medicine Products: